Abstract
The incidence of maternal-to-fetal human immunodeficiency virus type 1 (HIV-1) transmission is 25-30% in absence of antiretroviral therapy, and is inversely associated with Human leukocyte antigens (HLA) class-I discordance. Based on our earlier report that mixed lymphocyte reactions (MLR) induce a ribonuclease (RNase) that inhibits HIV-1 replication, we proposed that maternal-fetal alloantigen stimulation activates factors that protect the fetus against vertically- transmitted infections. We investigate here whether the degree of mother-infant HLA discordance associates with the ability to produce anti-HIV-1 alloantigen-stimulated factor (ASF), and affects placental RNases. We also determine whether such HLA association is influenced by the mothers HIV-1 status. Paired maternal and cord blood leukocytes were tested for the induction of ASF by MLR, and typed for HLA-A and – B. The placentas were tested for mRNA expression of three RNases. Neonate anti-mother, but not mother anti-neonate MLR generated supernatants with anti-HIV-1 activity, that was associated with HLA class I discordance. This HLA association was not seen in the HIV-infected cohort. HLA class I discordance was also associated with expression of placental RNase 1. Our findings are consistent with the hypothesis that HLA class I discordance induces expression of RNases in the placenta that contribute to innate host resistance to HIV-1 and other viral infections.
Keywords: Anti-HIV-1 activity, RNases, HLA class-I discordance
Current HIV Research
Title: Fetal-Maternal HLA-A and – B Discordance is Associated with Placental RNase Expression and Anti-HIV-1 Activity
Volume: 6 Issue: 4
Author(s): Victoria Ines Bedoya, Fabian Alberto Jaimes, Julio C. Delgado, Claudia Rugeles, Xiomara Usuga, Wildeman Zapata, Maria Eugenia Castano, Adriano Boasso, Gene Shearer and Maria Teresa Rugeles
Affiliation:
Keywords: Anti-HIV-1 activity, RNases, HLA class-I discordance
Abstract: The incidence of maternal-to-fetal human immunodeficiency virus type 1 (HIV-1) transmission is 25-30% in absence of antiretroviral therapy, and is inversely associated with Human leukocyte antigens (HLA) class-I discordance. Based on our earlier report that mixed lymphocyte reactions (MLR) induce a ribonuclease (RNase) that inhibits HIV-1 replication, we proposed that maternal-fetal alloantigen stimulation activates factors that protect the fetus against vertically- transmitted infections. We investigate here whether the degree of mother-infant HLA discordance associates with the ability to produce anti-HIV-1 alloantigen-stimulated factor (ASF), and affects placental RNases. We also determine whether such HLA association is influenced by the mothers HIV-1 status. Paired maternal and cord blood leukocytes were tested for the induction of ASF by MLR, and typed for HLA-A and – B. The placentas were tested for mRNA expression of three RNases. Neonate anti-mother, but not mother anti-neonate MLR generated supernatants with anti-HIV-1 activity, that was associated with HLA class I discordance. This HLA association was not seen in the HIV-infected cohort. HLA class I discordance was also associated with expression of placental RNase 1. Our findings are consistent with the hypothesis that HLA class I discordance induces expression of RNases in the placenta that contribute to innate host resistance to HIV-1 and other viral infections.
Export Options
About this article
Cite this article as:
Bedoya Ines Victoria, Jaimes Alberto Fabian, Delgado C. Julio, Rugeles Claudia, Usuga Xiomara, Zapata Wildeman, Castano Eugenia Maria, Boasso Adriano, Shearer Gene and Rugeles Teresa Maria, Fetal-Maternal HLA-A and – B Discordance is Associated with Placental RNase Expression and Anti-HIV-1 Activity, Current HIV Research 2008; 6 (4) . https://dx.doi.org/10.2174/157016208785132536
DOI https://dx.doi.org/10.2174/157016208785132536 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives
Current Molecular Pharmacology Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Polymeric Systems as Nanodevices for siRNA Delivery
Current Gene Therapy Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation